Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer

Annals of Surgery

Volumn 259, Issue 4, 2014, Pages 735-743

  Toiyama, Yuji ^a,b   Hur, Keun ^a   Tanaka, Koji ^b   Inoue, Yasuhiro ^b   Kusunoki, Masato ^b   Boland, C Richard ^a   Goel, Ajay ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b MIE UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; epithelial to mesenchymal transition; MiR 200c; noninvasive biomarker; prognostic marker

Indexed keywords

MICRORNA 200C;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER PROGNOSIS; CANCER RECURRENCE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE MARKER; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMAN; IN SITU HYBRIDIZATION; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICRORNA 200C BLOOD LEVEL; MIDDLE AGED; PREDICTION; PRIORITY JOURNAL; RANK SUM TEST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84895923572     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182a6909d     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: A consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143: 844-857.
3. Halama N, Herrmann C, Jaeger D, et al. Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer. Anticancer Res. 2008;28:4111-4115.
4. Meropol NJ, Schulman KA. Cost of cancer care: Issues and implications. J Clin Oncol. 2007;25:180-186.
5. DuffyMJ, Van Dalen A, Haglund C, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43:1348-1360.
6. Reiter W, Stieber P, Reuter C, et al. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res. 2000;20:5195-5198.
7. Fakih MG, Padmanabhan A. CEA monitoring in colorectal cancer. What you should know. Oncology. 2006;20:579-587.
8. Tan E, Gouvas N, Nicholls RJ, et al. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol. 2009;18:15-24.
9. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful Clin Chem. 2001;47:624-630.
10. Cortez MA, Calin GA. MicroRNA identification in plasma and serum: A new tool to diagnose and monitor diseases. Expert Opin Biol Ther. 2009;9:703-711.
11. Van Kouwenhove M, Kedde M, Agami R. MicroRNA regulation by RNAbinding proteins and its implications for cancer. Nat Rev Cancer. 2011;11: 644-656.
12. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513-10518.
13. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut. 2009;58:1375-1381.
14. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127:118-126.
15. Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol. 2012;36:e61-e67.
16. Pu XX, Huang GL, Guo HQ, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlatedwith p53 expression. JGastroenterol Hepatol. 2010;25: 1674-1680.
17. Cheng H, Zhang L, Cogdell DE, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One. 2011;6:e17745.
18. Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871-890.
19. Spaderna S, Schmalhofer O, Hlubek F, et al. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology. 2006;131:830-840.
20. Hugo H, Ackland ML, Blick T, et al. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol. 2007;213:374-383.
21. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442-454.
22. Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008;9:582-589.
23. Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009;11:1487-1495.
24. Hur K, Toiyama Y, Takahashi M, et al. MicroRNA-200c modulates epithelialto-mesenchymal transition (EMT) in human colorectal cancer metastasis [published online ahead of print July 10, 2012]. Gut. 2013;62:1315-1326. doi:10.1136/gutjnl-2011-301846.
25. Kroh EM, Parkin RK, Mitchell PS, et al. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010;50:298-301.
26. Link A, Balaguer F, Shen Y, et al. Fecal microRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev. 2010;19: 1766-1774.
27. ChangKH, Mestdagh P,Vandesompele J, et al. MicroRNAexpression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer. 2010;10:173.
28. Ruopp MD, Perkins NJ, Whitcomb BW, et al. Youden Index and optimal cutpoint estimated from observations affected by a lower limit of detection. Biom J. 2008;50:419-430.
29. Tominaga K, Nakanishi Y, Nimura S, et al. Predictive histopathologic factors for lymph node metastasis in patients with nonpedunculated submucosal invasive colorectal carcinoma. Dis Colon Rectum. 2005;48:92-100.
30. Egashira Y, Yoshida T, Hirata I, et al. Analysis of pathological risk factors for lymph node metastasis of submucosal invasive colon cancer. Mod Pathol. 2004;17:503-511.
31. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593-601.
32. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265-273.
33. Japanese Society for Cancer of the Colon and Rectum. Japanese Classification of Colorectal Carcinoma. 2nd English ed. Tokyo, Japan: Kanehara & Co, Ltd; 2009.